ATE519485T1 - Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine - Google Patents
Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserineInfo
- Publication number
- ATE519485T1 ATE519485T1 AT02739111T AT02739111T ATE519485T1 AT E519485 T1 ATE519485 T1 AT E519485T1 AT 02739111 T AT02739111 T AT 02739111T AT 02739111 T AT02739111 T AT 02739111T AT E519485 T1 ATE519485 T1 AT E519485T1
- Authority
- AT
- Austria
- Prior art keywords
- psychotherapy
- methods
- disorders
- brain
- those
- Prior art date
Links
- 238000001671 psychotherapy Methods 0.000 title abstract 4
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 title 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 title 1
- 230000001154 acute effect Effects 0.000 title 1
- 230000000144 pharmacologic effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 210000004556 brain Anatomy 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 230000003750 conditioning effect Effects 0.000 abstract 2
- 239000002831 pharmacologic agent Substances 0.000 abstract 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract 1
- 229960004373 acetylcholine Drugs 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229960002748 norepinephrine Drugs 0.000 abstract 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27986801P | 2001-03-29 | 2001-03-29 | |
| US36399102P | 2002-03-13 | 2002-03-13 | |
| PCT/US2002/009467 WO2002078629A2 (en) | 2001-03-29 | 2002-03-28 | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE519485T1 true ATE519485T1 (de) | 2011-08-15 |
Family
ID=26959924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02739111T ATE519485T1 (de) | 2001-03-29 | 2002-03-28 | Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7750030B2 (de) |
| EP (1) | EP1383465B1 (de) |
| JP (1) | JP2004530666A (de) |
| AT (1) | ATE519485T1 (de) |
| AU (1) | AU2002311784B2 (de) |
| CA (1) | CA2442330A1 (de) |
| WO (1) | WO2002078629A2 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| CA2442330A1 (en) | 2001-03-29 | 2002-10-10 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| US20050096396A1 (en) * | 2002-03-28 | 2005-05-05 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| WO2005016319A2 (en) * | 2003-08-06 | 2005-02-24 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| CA2530014A1 (en) * | 2003-08-27 | 2005-03-10 | Eli Lilly And Company | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors |
| KR20070007276A (ko) * | 2003-12-29 | 2007-01-15 | 제이슨 맥데빗 | 재발성 의학적 증상을 치료하기 위한 조성물 및 방법 |
| EP1779867A4 (de) * | 2004-07-01 | 2009-12-02 | Eisai R&D Man Co Ltd | Mittel zur förderung der nervenreveneration |
| US20060084659A1 (en) * | 2004-10-19 | 2006-04-20 | Michael Davis | Augmentation of psychotherapy with cannabinoid reuptake inhibitors |
| EP2258358A3 (de) * | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenese mit Acetylcholinesterasehemmer |
| EP2275095A3 (de) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenese durch modulation des Muscarinrezeptors |
| WO2008013860A2 (en) * | 2006-07-28 | 2008-01-31 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use |
| WO2008098245A2 (en) * | 2007-02-09 | 2008-08-14 | University Of Georgia Reseach Foundation, Inc. | Nmda receptor modulation and treatments for addictive behavior |
| WO2008124814A2 (en) * | 2007-04-10 | 2008-10-16 | Mcdevitt Jason P | Sublingual formulations of d-cycloserine and methods of using same |
| US20090298025A1 (en) * | 2007-05-09 | 2009-12-03 | Oregon Health & Science University | Object recognition testing tools and techniques for measuring cognitive ability and cognitive impairment |
| US9560967B2 (en) | 2008-04-24 | 2017-02-07 | The Invention Science Fund I Llc | Systems and apparatus for measuring a bioactive agent effect |
| US9662391B2 (en) | 2008-04-24 | 2017-05-30 | The Invention Science Fund I Llc | Side effect ameliorating combination therapeutic products and systems |
| US9064036B2 (en) | 2008-04-24 | 2015-06-23 | The Invention Science Fund I, Llc | Methods and systems for monitoring bioactive agent use |
| US9449150B2 (en) | 2008-04-24 | 2016-09-20 | The Invention Science Fund I, Llc | Combination treatment selection methods and systems |
| US9649469B2 (en) | 2008-04-24 | 2017-05-16 | The Invention Science Fund I Llc | Methods and systems for presenting a combination treatment |
| US9026369B2 (en) | 2008-04-24 | 2015-05-05 | The Invention Science Fund I, Llc | Methods and systems for presenting a combination treatment |
| US9282927B2 (en) | 2008-04-24 | 2016-03-15 | Invention Science Fund I, Llc | Methods and systems for modifying bioactive agent use |
| US9239906B2 (en) | 2008-04-24 | 2016-01-19 | The Invention Science Fund I, Llc | Combination treatment selection methods and systems |
| US20100204291A1 (en) * | 2009-02-12 | 2010-08-12 | Mcdevitt Jason P | Method for Facilitating Extinction Training Using D-Cycloserine |
| CN107868071B (zh) | 2012-11-05 | 2021-07-20 | 爱默蕾大学 | 7,8-二羟黄酮和7,8-取代的黄酮衍生物、组合物及其相关方法 |
| US9877951B2 (en) | 2015-02-12 | 2018-01-30 | College Of William And Mary | Method for treating dementia |
| US20230310399A1 (en) * | 2020-07-24 | 2023-10-05 | Cognifisense, Inc. | Combinatorial therapeutic systems and methods that include systemic, centrally and peripherally acting analgesics |
| WO2024091523A1 (en) * | 2022-10-24 | 2024-05-02 | 2A Biosciences, Inc. | Conformationally restricted phenethylamine analogs |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR7131M (de) * | 1968-01-31 | 1969-07-21 | ||
| US4727062A (en) | 1986-03-17 | 1988-02-23 | Merck & Co., Inc. | 3-Halovinylglycine antibacterial agents |
| US5087633A (en) * | 1987-12-01 | 1992-02-11 | G. D. Searle & Co. | Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder |
| US4904681A (en) * | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
| US5468763A (en) * | 1987-12-01 | 1995-11-21 | G. D. Searle & Co. | Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder |
| US5187171A (en) | 1989-01-09 | 1993-02-16 | G. D. Searle & Co. | Use of a glycine b partial agonist as an antipsychotic |
| US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| JPH03236315A (ja) | 1989-12-05 | 1991-10-22 | Nippon Oil & Fats Co Ltd | 抗精神病薬 |
| US5260324A (en) * | 1990-02-06 | 1993-11-09 | G. D. Searle & Company | Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| US5086072A (en) * | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| US5194371A (en) | 1991-07-31 | 1993-03-16 | Bristol-Myers Squibb Company | Production of pradimicin antibiotics |
| US5854217A (en) * | 1992-09-28 | 1998-12-29 | Bearsden Bio, Inc. | Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function |
| US5428069A (en) * | 1993-01-11 | 1995-06-27 | The United States Of America As Represented By The Department Of Health & Human Services | Treating cognition with, aminocyclopropanecarboxylic derivatives |
| US5523323A (en) * | 1993-09-14 | 1996-06-04 | Maccecchini; Maria-Luisa | Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence |
| AU4128896A (en) | 1994-11-23 | 1996-06-17 | G.D. Searle & Co. | Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury |
| WO1996015788A1 (en) * | 1994-11-23 | 1996-05-30 | G.D. Searle & Co. | Use of amino-isoxazolidone compounds for improvement of implicit memory |
| US6271015B1 (en) * | 1995-06-12 | 2001-08-07 | The Scripps Research Institute | Fatty-acid amide hydrolase |
| US6355681B2 (en) * | 1995-12-07 | 2002-03-12 | Glytech, Inc. | Glycine substitutes and precursors for treating a psychosis |
| UA56257C2 (uk) * | 1997-09-23 | 2003-05-15 | Елі Ліллі Енд Компані | Спосіб лікування неадекватної визивної поведінки |
| UA57107C2 (uk) * | 1997-09-23 | 2003-06-16 | Елі Ліллі Енд Компані | Спосіб лікування розладу поведінки |
| US6391922B1 (en) * | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| EP1073432B1 (de) * | 1998-04-14 | 2007-08-15 | The General Hospital Corporation | Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie |
| US7067545B1 (en) | 1998-06-10 | 2006-06-27 | Meiji Seika Kaisha Ltd. | Remedies for spinocerebellar ataxia and compositions for treating spinocerebellar ataxia |
| US6943166B1 (en) * | 1999-04-30 | 2005-09-13 | Lilly Icos Llc. | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
| US6333357B1 (en) * | 1999-11-05 | 2001-12-25 | Be Able, Llc | Behavior chemotherapy |
| US6462054B1 (en) * | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| US20020156112A1 (en) * | 2000-11-15 | 2002-10-24 | Bamdad R. Shoshana | Endostatin-like angiogenesis inhibition |
| WO2005016319A2 (en) | 2003-08-06 | 2005-02-24 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| US20050096396A1 (en) * | 2002-03-28 | 2005-05-05 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| CA2442330A1 (en) | 2001-03-29 | 2002-10-10 | Emory University | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| US6562846B2 (en) * | 2001-04-27 | 2003-05-13 | Bristol-Myers Squibb Company | Bisarylimidazolyl fatty acid amide hydrolase inhibitors |
| US6949574B2 (en) * | 2002-02-08 | 2005-09-27 | Bristol-Myers Squibb Company | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors |
| WO2003097573A1 (en) * | 2002-05-16 | 2003-11-27 | Sepracor, Inc. | Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
| EA010267B1 (ru) * | 2002-10-07 | 2008-06-30 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Модуляция тревоги через блокаду гидролиза анандамида |
| IL154318A (en) | 2003-02-06 | 2010-05-31 | Sarah Herzog Memorial Hospital | Pharmaceutical compositions for the treatment of movement disorders |
| KR20070007276A (ko) * | 2003-12-29 | 2007-01-15 | 제이슨 맥데빗 | 재발성 의학적 증상을 치료하기 위한 조성물 및 방법 |
| US20060084659A1 (en) * | 2004-10-19 | 2006-04-20 | Michael Davis | Augmentation of psychotherapy with cannabinoid reuptake inhibitors |
-
2002
- 2002-03-28 CA CA002442330A patent/CA2442330A1/en not_active Abandoned
- 2002-03-28 US US10/473,640 patent/US7750030B2/en not_active Expired - Fee Related
- 2002-03-28 JP JP2002576897A patent/JP2004530666A/ja not_active Withdrawn
- 2002-03-28 EP EP02739111A patent/EP1383465B1/de not_active Expired - Lifetime
- 2002-03-28 WO PCT/US2002/009467 patent/WO2002078629A2/en not_active Ceased
- 2002-03-28 AU AU2002311784A patent/AU2002311784B2/en not_active Ceased
- 2002-03-28 AT AT02739111T patent/ATE519485T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1383465B1 (de) | 2011-08-10 |
| CA2442330A1 (en) | 2002-10-10 |
| AU2002311784B2 (en) | 2007-11-22 |
| EP1383465A2 (de) | 2004-01-28 |
| US20040208923A1 (en) | 2004-10-21 |
| WO2002078629A2 (en) | 2002-10-10 |
| AU2002311784B8 (en) | 2002-10-15 |
| WO2002078629A3 (en) | 2002-11-28 |
| JP2004530666A (ja) | 2004-10-07 |
| US7750030B2 (en) | 2010-07-06 |
| EP1383465A4 (de) | 2009-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE519485T1 (de) | Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine | |
| AU6110301A (en) | Diagnostics and therapeutics for macular degeneration-related disorders | |
| DK1355889T3 (da) | Substituerede triazoldiaminderivater som kinaseinhibitorer | |
| AR039832A1 (es) | Catalizadores de reforma de bismuto y fosforo, su metodo de elaboracion y el proceso de reforma de nafta | |
| MXPA01004895A (es) | Metodo y sistema para seleccionar, modificar y operar electronicamente un progrma de motivacion o reconocimiento. | |
| SG147442A1 (en) | Methods and reagents for the treatment of immunoinflammatory disorders | |
| NO20010539L (no) | Behandling av avhengighet og avhengighet-relatert oppforsel | |
| DE602006017123D1 (de) | Einrichtungen und verfahren zum garantieren von dienstanforderungen auf benutzergerätebasis in einen träger | |
| IL148071A0 (en) | Method for treatment of symptoms of central nervous system disorders | |
| DE60207289D1 (de) | Verfahren und vorrichtung zur symmetrischen schlüsselerzeugung in einer persönlichen sicherheitsvorrichtung mit begrenzten vertrauensbeziehungen | |
| BR9916544A (pt) | Processo para tratamento de neoplasia em um indivìduo que necessita de tal tratamento, e, combinação | |
| DE60226755D1 (de) | Verfahren und vorrichtung für einen computerfirewall | |
| WO2004003550A3 (en) | Individualization of therapy with anticoagulants | |
| WO2002073196A3 (en) | Individualization of therapy with antipsychotics | |
| ATE508292T1 (de) | Verfahren und vorrichtung zur verbindung von komponenten | |
| ATE406517T1 (de) | Kraftstoffinjektor | |
| CY1110202T1 (el) | Νεοι συνδυασμοι ενος αντι εμετικου παραγοντα και ενος αναστολεα της εγκεφαλινασης | |
| WO2002095402A3 (en) | Individualization of therapy with hyperlipidemia agents | |
| ATA16902001A (de) | Trag- bzw. führungsvorrichtung für flugzeugkomponenten | |
| ATE289526T1 (de) | Flüssigkeitsverteiler für kolonnen | |
| WO2002071060A3 (en) | Use of metabolic phenotyping in individualized treatment with amonafide | |
| ATE287982T1 (de) | Coregarn | |
| WO2005016319A3 (en) | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning | |
| WO2002090994A3 (en) | Individualization of therapy with analgesics | |
| WO2002099422A3 (en) | Individualization of therapy with alzheimer's disease agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |